NUTX · Nutex Health Inc. · Stock research

# NUTX — Nutex Health, Inc.

Current Thesis

The re-rating leg that carried Nutex from the July 2025 short-report wreckage to a $204.00 52-week high has stalled. Shares closed 2026-07-17 at $162.98 after five consecutive down days, roughly 20% below the high and well under the $196.53 area where B. Riley's 2026-06-26 Buy initiation ($290 target) landed. The engine underneath is unchanged: a micro-hospital operator whose earnings inflection is manufactured by routing 50–60% of out-of-network claims through No Surprises Act Independent Dispute Resolution. TTM revenue through 2026-03-31 is $880.0M against $247.6M in FY2023. What has changed is that the market is now pricing the collectibility question rather than the growth rate, and a Q2 print lands inside the next two weeks. The narrative has moved from ACCELERATING to MATURING, with the pullback carrying real information rather than being simple consolidation.

Bullish and bearish views on Nutex Health Inc.

The model's bull view on Nutex Health Inc. (NUTX), in brief: The cash is banked, not accrued into a receivable. The bear view: The true-up already happened once. A one-time cumulative $55.0M reversal covering 18,950 arbitration claims determined ineligible under the IDR process for July 2024 through December 2025, triggered by a mid-2025 CMS directive ordering certified IDR entities to clear their… Both cases follow in full.

Bull Case

• The cash is banked, not accrued into a receivable. Q1 FY2026 (quarter ended 2026-03-31): revenue $216.5M, net income attributable to Nutex $46.8M (+120.6% vs $21.2M), diluted EPS $6.52, operating cash flow $75.5M (+48% YoY), cash and restricted cash $210.6M. Operating income of $81.3M on $216.5M of revenue is a 37.6% margin.
• Valuation is not the constraint. At $162.98 the market cap is $1.12B against a trailing P/E of 12.70. Consensus price target sits at $243.33; B. Riley's $290 (2026-06-26) is the high mark and the first sell-side coverage the name has ever carried.
• Arbitration mechanics were still working at the last check. Disclosed win rate above 85% of award determinations, average collection above 80% of award amounts, arbitration costs running ~35% of arbitration revenue.
• Any upside surprise on 2026-07-30 forces covering into almost no supply.
• Management is buying, not distributing. ~$30.4M of insider purchases in the quarter ended 2026-03-31 with no reported sales above the $5M threshold, $31.7M repurchased in Q1, and a second $25.0M repurchase authorization announced alongside the Q1 release.
• Capital allocation is shifting toward owned assets. The Q1 announcement included a move to directly developing new hospital facilities rather than the prior JV-heavy model, which reduces long-run dependence on arbitration recoveries if executed.

Bear Case

• The true-up already happened once. A one-time cumulative $55.0M reversal covering 18,950 arbitration claims determined ineligible under the IDR process for July 2024 through December 2025, triggered by a mid-2025 CMS directive ordering certified IDR entities to clear their dispute backlog. That is the collectibility risk materialising in the reported numbers, and it establishes that the eligibility screen is being applied retroactively.
• The SEC is investigating the revenue line itself. The inquiry concerns whether Nutex failed to disclose vendor HaloMD's legal exposure and the potential uncollectibility of arbitration revenue. A securities class action covering purchasers from July 2024 to July 2025 and a shareholder derivative suit are both live.
• The short thesis quantified the exposure. Blue Orca's 2025-07-22 report alleged HaloMD submitted inflated and ineligible arbitration claims and put $479.9M of 2024 revenue — close to 30% of the total — at risk. The $55.0M true-up is a fraction of that estimate, which leaves the tail open.
• Court enforcement is narrowing. A 2025 Fifth Circuit ruling limits providers' ability to compel payment of IDR awards through the courts, weakening the backstop behind the >80% collection assumption.
• Accrual build is outrunning the base business. Q1 arbitration costs $46.1M, accrued arbitration expense $56.8M, accounts payable to the IDR vendor $38.1M at 2026-03-31. Same-hospital revenue grew 0.2% and same-hospital visits 3.1% — strip the recoveries and the operating business is roughly flat.
• Consensus expects a sequential decline. Q2 FY2026 estimates cluster near $4.60 EPS on $219.29M revenue, below the $6.52 printed in Q1.

Setup & Price Structure

Five straight red days into 2026-07-17 took the stock from the $196 area to $162.98, with a 2026-07-17 intraday range of $157.82–$167.75. The 52-week band is $77.21–$204.00, so the name still sits at roughly 2.1x its lows while giving back the entire June acceleration. The B. Riley initiation on 2026-06-26 marked the local top rather than starting a new leg, which is the pattern that follows first coverage on an under-owned microcap when the buyers are already in. The rising base built through spring sits in the $145–$155 zone; that shelf is what the current slide is testing. A microcap with a 4.5M float and 16% short interest does not decline gently on no news, so the persistence of the selling ahead of an earnings date deserves more weight than the absolute percentage. Fresh entries into a five-day slide that runs directly into a binary print offer no edge — the setup either reclaims the $175–$180 area on volume and rebuilds a structure, or it works the spring base and becomes a different trade entirely.

Catalyst Calendar (next 30 days)

• ~2026-07-30 (est.) — Q2 FY2026 earnings. This is the dominant event. Sources split between a 2026-07-30 and a 2026-08-12 date; the earlier one governs risk. The lines that matter: arbitration win rate, average collection percentage, any further true-up of ineligible claims, and the accrued arbitration expense balance versus the $56.8M at 2026-03-31.
• Ongoing through August — SEC investigation. No statutory disclosure date; any 8-K on the matter is an unscheduled 10–20% event given the float.
• Ongoing — securities class action and derivative suit docket activity; motion-to-dismiss rulings are not calendared but are live.
• ~2026-08-15 (est.) — quarterly 13F season and the next short-interest settlement updates, which will show whether the 15.6–16.2% short position was added to or covered through the June high.

What Would Change Our Mind

A weekly close below $150 forfeits the spring base and the entire June breakout structure, which would reclassify the move since March as a completed squeeze rather than a re-rating. Above that, the Q2 print is the arbiter: a second true-up of ineligible claims, a collection percentage disclosed below 80%, or a win rate under 85% would confirm that the CMS backlog directive permanently reset the earnings engine rather than clearing a one-time backlog. On the other side, a print that holds collection rates with no new reversal, paired with a reclaim of $180 on expanding volume, restores the accelerating read and makes the current drawdown the pullback that a MATURING theme is supposed to offer. An SEC enforcement action or an adverse ruling on IDR award collectibility ends the thesis at any price.

Correlation Notes

Correlation to broad healthcare services indices is weak — this trades on its own regulatory docket, not on managed-care sector flow. The relevant peer set is other No Surprises Act arbitration beneficiaries and out-of-network billing operators, where a single adverse CMS or court development marks the entire cohort simultaneously. Secondary correlation runs to the low-float squeeze complex: with 16% short interest and a 4.5M float, moves are amplified by borrow dynamics that have nothing to do with hospital operations. Position sizing should reflect that the same headline can produce a 10–20% single-day gap in either direction, which caps prudent exposure at probe size regardless of how attractive the 12.7x multiple looks against the $243.33 consensus target.